Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

hem-onc-updates

Advertisement

AYVAKIT® (Avapritinib)

August 19, 2021August 19, 2021 RR FDA Approvals
General Medical Oncology & Hematology

The FDA on June 16, 2021, approved AYVAKIT® for adult patients with advanced Systemic Mastocytosis, including patients with aggressive Systemic Mastocytosis, Systemic Mastocytosis with an associated hematological neoplasm, and Mast Cell Leukemia. AYVAKIT® is a product of Blueprint Medicines Corp.

Related Posts:

  • AYVAKIT® (Avapritinib)
  • FDA Approves AYVAKIT®, a Precision Therapy, for…

Post navigation

TRUSELTIQ® (Infigratinib)
FDA Approves LENVIMA® Plus KEYTRUDA® for Advanced Renal Cell Carcinoma

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

Oncoprescribe-Ad

Advertisement

Ad 2

OncoPrescribe-CDC

Advertisement

Ad 3

Oncoprescribe-Ad

Advertisement

Ad 4

OncoPrescribe

Advertisement

  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved